Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer

Journal:

Journal of Hepatology

Published:

2025-11-25

DOI:

10.1016/j.jhep.2025.10.032

Affiliations:

6

Authors:

11

Go to article

Institutions	Authors	Share
Seoul National University Hospital (SNUH), South Korea	3.000000	0.27
Seoul National University Bundang Hospital (SNUBH), South Korea	2.000000	0.18
Yonsei Cancer Hospital, South Korea	2.000000	0.18
Seoul St. Mary's Hospital, South Korea	2.000000	0.18
CHA Bundang Medical Center, South Korea	2.000000	0.18

Interested in Oncology and Carcinogenesis?